1
|
Leone AG, Miceli R, Trapani D, Massagrande M, Morano F, Marsoni S, La Verde N, Berardi R, Casolino R, Lambertini M, Dalu D, Di Maio M, Beretta GD, Perrone F, Cinieri S, Pietrantonio F. Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology. ESMO Open 2023; 8:101578. [PMID: 37270870 DOI: 10.1016/j.esmoop.2023.101578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2023] [Revised: 04/23/2023] [Accepted: 04/29/2023] [Indexed: 06/06/2023] Open
Abstract
BACKGROUND Transgender and gender-diverse (TGD) population represents an underserved group across the cancer care continuum. To assess the perspective of both oncology health care providers (OHPs) and TGD individuals in Italy, we conducted two national surveys: one among 2407 OHPs about their attitudes, knowledge and behavior toward TGD patients, and one among TGD persons about their health needs, experiences and barriers encountered in the use of health services across the cancer continuum. MATERIALS AND METHODS The surveys were self-compiled web-based computer-aided web interview, conducted in Italy within the 'OncoGender-Promoting Inclusion in Oncology' project, led by the Italian national cancer society [Associazione Italiana di Oncologia Medica (AIOM)]-associated researchers. All members of AIOM were invited by e-mail to participate in the OHP survey. TGD persons were reached through advocacy groups and consumers' panel. The recruitment was completed on a voluntary basis. Survey data were collected and managed using an online platform managed by ELMA Research, an independent pharmaceutical marketing agency. RESULTS A total of 305 OHPs (13% of AIOM members) and 190 TGD individuals participated in the surveys. Only 19% of OHPs felt competent in providing care to TGD patients and 21% declared not to feel comfortable in treating TGD patients. Seventy-one percent of TGD persons reported that they had never joined any cancer screening program; 32% reported one or more acts of discrimination by health care providers. Seventy-two percent of OHPs recognized the lack of specific education on cancer care for TGD patients and deemed it necessary to receive adequate training. CONCLUSIONS A general lack of knowledge among OHPs about TGD health issues seems to be the main driver of difficulties in providing assistance and of discriminatory attitudes against TGD individuals. Ultimately, this whole issue generates access barriers and contributes to lack of trust in health care services. Educational interventions and an implementation of person-centric cancer policies are urgently needed.
Collapse
Affiliation(s)
- A G Leone
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - R Miceli
- Department of Biostatistics for Clinical Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - D Trapani
- European Institute of Oncology, Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Milan, Italy; Department of Oncology and Hematology (DIPO), University of Milan, Milan, Italy
| | | | - F Morano
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S Marsoni
- IFOM-The FIRC Institute of Molecular Oncology, Milan, Italy
| | - N La Verde
- Department of Oncology, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - R Berardi
- Oncology Clinic, Università Politecnica delle Marche, AOU delle Marche, Ancona, Italy
| | - R Casolino
- Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - M Lambertini
- Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genova, Genova, Italy; Department of Medical Oncology, U.O. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genova, Italy
| | - D Dalu
- Department of Oncology, Luigi Sacco Hospital, ASST Fatebenefratelli Sacco, Milan, Italy
| | - M Di Maio
- Department of Oncology, University of Turin, A.O. Ordine Mauriziano, Turin, Italy
| | - G D Beretta
- UOC Oncologia Medica, ASL Pescara P.O., Pescara, Italy
| | - F Perrone
- Clinical Trial Unit, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy
| | - S Cinieri
- Medical Oncology Unit, Ospedale di Summa A. Perrino, Brindisi, Italy
| | - F Pietrantonio
- Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
| |
Collapse
|
2
|
Dalu D, Cona M, De Francesco D, Ammoni L, Rota S, Fasola C, Foschi A, La Verde N. 1640P Pegylated liposomal doxorubicin (PLD) as first line treatment in AIDS-related Kaposi’s sarcoma (AIDS-KS): A single institution retrospective study. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1866] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022] Open
|
3
|
Cona M, Dalu D, Ferrario S, Tosca N, Gambaro A, Filipazzi V, Rota S, La Verde N. 1570P The emotional impact of COVID-19 outbreak on cancer out-patients and their caregivers: Impressions from the heart of the Italian pandemic. Ann Oncol 2020. [PMCID: PMC7506410 DOI: 10.1016/j.annonc.2020.08.2053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
5
|
Dalu D, Fasola C, Bombonati G, De Francesco D. CHEMOTHERAPY IN HIV-POSITIVE PATIENTS WITH NON-HODGKIN LYMPHOMA: A SINGLE INSTITUTION RETROSPECTIVE STUDY. Hematol Oncol 2019. [DOI: 10.1002/hon.217_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- D. Dalu
- Oncology Unit; Ospedale L. Sacco-Polo Universitario ASST FBF-Sacco; Milan Italy
| | - C. Fasola
- Oncology Unit; Ospedale L. Sacco-Polo Universitario ASST FBF-Sacco; Milan Italy
| | - G. Bombonati
- Oncology Unit; Ospedale L. Sacco-Polo Universitario ASST FBF-Sacco; Milan Italy
| | - D. De Francesco
- Department of Infection and Population Health; UCL; London United Kingdom
| |
Collapse
|
6
|
Rindone G, Bandera A, Brioschi F, Dalu D, Pagni F, Vitiello P, Mena M, Fasola C, Rossi M, Crippa F, Suardi E, Epifani R, Zeroli C, Serio G, Cocito F, Doni E, Giglio O, Rossi R, Gori A, Gambacorti Passerini C, Verga L. A RETRO-PROSPECTIVE STUDY IN HIV+ PATIENTS AFFECTED BY LYMPHOMA: THE MUSTHAL MULTICENTER EXPERIENCE IN NORTHERN ITALY. Hematol Oncol 2019. [DOI: 10.1002/hon.216_2631] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- G. Rindone
- Clinic of Hematology; ASST Monza « San Gerardo» Hospital, University of Milano-Bicocca; Monza Italy
| | - A. Bandera
- Departement of Internal Medicine; Department of Pathophysiology and Transplantation, School of Medicine and Surgery, University of Milan, Milan, Italy, Infectious Diseases Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milan Italy
| | - F.A. Brioschi
- Clinic of Hematology; ASST Monza « San Gerardo» Hospital, University of Milano-Bicocca; Monza Italy
| | - D. Dalu
- Department of Oncology; Oncology Unit, « L. Sacco» Hospital, University of Milan; Milan Italy
| | - F. Pagni
- Surgical Department; Pathology Unit, ASST Monza « San Gerardo» Hospital, University of Milano-Bicocca; Monza Italy
| | - P. Vitiello
- Clinic of Infectious Disease; ASST Monza, «San Gerardo Hospital», University of Milano-Bicocca; Monza Italy
| | - M. Mena
- Medical Area Department; Infectious Disease Unit, Legnano Hospital; Legnano Italy
| | - C. Fasola
- Department of Oncology; Oncology Unit, « L. Sacco» Hospital, University of Milan; Milan Italy
| | - M. Rossi
- Clinic of Infectious Disease; ASST Monza, «San Gerardo Hospital», University of Milano-Bicocca; Monza Italy
| | - F. Crippa
- Department of Health Sciences; Infectious and Tropical Disease Unit, San Paolo Hospital, University of Milano; Milan Italy
| | - E. Suardi
- Department of Health Sciences; Infectious and Tropical Disease Unit, San Paolo Hospital, University of Milano; Milan Italy
| | - R. Epifani
- Department of Oncology; Oncology Unit, Sant'Anna Hospital; Como Italy
| | - C. Zeroli
- Department of Internal Medicine, Infectiuos Disease Unit; ASST Valle Olona, Busto Arsizio Hospital; Busto Arsizio Italy
| | - G. Serio
- Pathology Department; Pathology Unit, ASST Valle Olona, Busto Arsizio Hospital; Busto Arsizio Italy
| | - F. Cocito
- Clinic of Hematology; ASST Monza « San Gerardo» Hospital, University of Milano-Bicocca; Monza Italy
| | - E. Doni
- Clinic of Hematology; ASST Monza « San Gerardo» Hospital, University of Milano-Bicocca; Monza Italy
| | - O. Giglio
- Department of Internal Medicine; Infectious Disease Unit, Sant'Anna Hospital; Como Italy
| | - R.S. Rossi
- Pathology Department; Pathology Unit, « L. Sacco» Hospital, University of Milan; Milan Italy
| | - A. Gori
- Departement of Internal Medicine; Department of Pathophysiology and Transplantation, School of Medicine and Surgery, University of Milan, Milan, Italy, Infectious Diseases Unit Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico; Milan Italy
| | - C. Gambacorti Passerini
- Clinic of Hematology; ASST Monza « San Gerardo» Hospital, University of Milano-Bicocca; Monza Italy
| | - L. Verga
- Clinic of Hematology; ASST Monza « San Gerardo» Hospital, University of Milano-Bicocca; Monza Italy
| |
Collapse
|
7
|
Filipazzi V, Dalu D, Isabella L, Tosca N, Ferrario S, Gambaro A, Somma L, Fasola C, Pellegrini I, Bombonati G, Curcio R, Damiani E, Cattaneo M. Efficacy and safety of Nab-paclitaxel plus gemcitabine in metastatic pancreatic cancer. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx425.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
8
|
Latocca M, Dalu D, Fasola C, Filipazzi V, Ferrario S, Tosca N, Brioschi F, Bandera A, Verga L, De Francesco D, Piazza E. Retrospective analysis of patients affected by diffuse large B cell lymphomas AIDS-related. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw345.45] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
9
|
Filipazzi V, Ferrari L, De Masi P, Cattaneo M, Latocca M, Fasola C, Dalu D, Piazza E. Maintenance treatment with pemetrexed in NSCLC. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.44] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Bertolini AS, Fusco O, Berardi E, Malugani F, Fiumanò M, Doria A, Pedroncelli S, Filipazzi V, Dalu D, Menatti E. Screening for chemotherapy-induced reactivation of hepatitis B virus infection: An institutional experience. J Clin Oncol 2008. [DOI: 10.1200/jco.2008.26.15_suppl.20563] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|